Option Care выбрана в качестве национального поставщика CUVITRU
By: Option Care
December 1, 2016
BANNOCKBURN, Ill., November 29, 2016 — Option Care Enterprises, Inc., one of the nation’s leading providers of home and alternate treatment site infusion services, has been selected as a contracted provider of a new 20% formulation of subcutaneous immunoglobulin (SCIG) therapy for primary immunodeficiency (PI). CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] is manufactured by Shire plc.
CUVITRU™ recently was approved by the U.S. Food and Drug Administration to treat adult and pediatric patients two years and older with PI, a group of more than 300 genetic disorders in which part of the body’s immune system is missing or functions improperly.
“Option Care has a proven track record of providing compassionate, high-quality clinical care in the home or at alternate treatment sites to patients undergoing therapy for a variety of complex conditions, including those with primary immunodeficiency,” said Lisa Betts, Vice President, Specialty Programs, Option Care. “As one of the largest national providers of immunoglobulin therapy, we are pleased to offer CUVITRU™ to support primary immunodeficiency patients as we continue to spread awareness and improve treatment options. “
Immunoglobulin (IG) is a lifelong therapy provided to prevent recurrent infections in patients with PI, which affects as many as six million people worldwide.
В Option Care работают более 1800 клинических специалистов, включая фармацевтов, и более 1200 специалистов инфузионной терапии. Такой междисциплинарный подход к подбору команды специально обученных клинических специалистов позволяет составлять персонализированные планы лечения пациентов, осуществлять клинический мониторинг каждого сеанса инфузионной терапии, комплексно обучать и информировать пациентов и ухаживающих за ними лиц. Чтобы получить более подробную информацию, обратитесь в специализированный передовой центр иммуноглобулинотерапии Option Care по телефону 1-877-974-4844 или по факсу 877-974-4845.
О компании Option Care
Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all acute and chronic patients across the United States. Learn more at www.OptionCare.com.
###
You might also be interested in:
Adverse Drug Events Rare Among Patients Receiving Home Infusion Autoimmune Therapy
NEW ORLEANS — Adverse drug events (ADE) were rare — and serious ADEs nonexistent — in a retrospective two-year study of nearly 1,900 home and alternate treatment site (ATS) infusions of infliximab for patients with autoimmune disorders.1 The research was presented today by Option Care, a leading provider of home and ATS infusion services, at […]
Компания Option Care является национальным поставщиком услуг инфузионной терапии на дому с использованием первого лекарства от БАС, одобренного Управлением США по контролю качества пищевых продуктов и лекарственных средств за последние 20 лет
BANNOCKBURN, Ill., Sept. 6, 2017 — Option Care Enterprises, Inc., the nation’s largest independent provider of home and alternate treatment site infusion services, has signed an agreement to become a national contracted home infusion provider for ALS drug RADICAVATM (edaravone), an intravenous (IV) infusion treatment for amyotrophic lateral sclerosis (ALS). RADICAVA, the first ALS treatment […]